NCT06334419View on ClinicalTrials.gov

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Fragile X Syndrome
Interventions
DRUG

Gaboxadol

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

DRUG

Placebo

Two placebo capsules

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

Healx Limited

INDUSTRY

lead

Craig Erickson

OTHER

NCT06334419 - Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS) | Biotech Hunter | Biotech Hunter